Shionogi Income from Continuous Operations 2021-2024 | SGIOY

Shionogi income from continuous operations for the twelve months ending December 31, 2024 was $0.767B, a 1.79% decline year-over-year.

  • Shionogi annual income from continuous operations for 2025 was $1.119B, a 0.99% increase from 2024.
  • Shionogi annual income from continuous operations for 2024 was $1.108B, a 18.85% decline from 2023.
  • Shionogi annual income from continuous operations for 2023 was $1.365B, a 35.23% increase from 2022.

Shionogi Income from Continuous Operations 2021-2024 | SGIOY

  • Shionogi annual income from continuous operations for 2025 was $1.119B, a 0.99% increase from 2024.
  • Shionogi annual income from continuous operations for 2024 was $1.108B, a 18.85% decline from 2023.
  • Shionogi annual income from continuous operations for 2023 was $1.365B, a 35.23% increase from 2022.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Zoetis (ZTS)$67.7B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$46.1B
BeOne Medicines - (ONC)$31.9B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$17.2B
United Therapeutics (UTHR)$13.7B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$8B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B